Product Description
Symvivos bacTRL platform technology delivers plasmid DNA, both orally and through IV administration, that enables a patients own cells to produce biologics.
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Symvivo Corporation
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: COVID-19
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04334980 |
bacTRL-Spike-1 | P1 |
Completed |
COVID-19 |
2022-08-31 |
36% |
2022-10-26 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/19/2021 |
News Article |
Symvivo Corporation receives funding for COVID-19 Vaccine Program |
|
11/02/2020 |
News Article |
First Healthy Volunteer Dosed in Symvivo's Phase 1 Clinical Trial of bacTRL-Spike™, an Oral COVID-19 Vaccine Candidate |